CRISPR-Cas genome editing in ex-vivo human lungs to rewire the translational path of genome-targeting therapeutics.
Mesaki K, Yamamoto H, Juvet S, Yeung J, Guan Z, Akhter A, Yao Y, Dickie C, Mangat H, Wang A, Wilson GW, Mariscal A, Hu J, Davidson AR, Kleinstiver BP, Cypel M, Liu M, Keshavjee S.
Mesaki K, et al. Among authors: davidson ar.
Hum Gene Ther. 2024 May 8. doi: 10.1089/hum.2023.223. Online ahead of print.
Hum Gene Ther. 2024.
PMID: 38717950